Antiplatelet Therapy and Cardiovascular Diseases

Triglyceride Polygenic Score Identifies Differential Bleeding and Cardiovascular Risk with Aspirin in Primary Prevention

This paper finds that a triglyceride-related polygenic score modifies aspirin's effects on bleeding and cardiovascular events in older adults, with different outcomes based on genetic risk profiles.

The zebrafish model tackles anti-P2Y12 variability in humans: a translational approach

This paper uses zebrafish models to study miR-150's role in platelet function and resistance to P2Y12 inhibitors, finding that miR-150 downregulates MASTL, leading to reduced VASP phosphorylation and clopidogrel resistance in humans.

A Prospective Observational Study to Assess the Impact of Pharmacogenetics on Outcomes in Vascular Surgery (PROSPER)

This study investigates how CYP2C19 genetic variants affect outcomes in CLTI patients taking clopidogrel post-revascularisation.

Implementing a Pharmacogenomic-driven Algorithm to Guide Antiplatelet Therapy among Caribbean Hispanics: A Nonrandomized Prospective Cohort Study.

This study evaluates a pharmacogenomic-driven algorithm to guide antiplatelet therapy in Caribbean Hispanic patients post-PCI, showing reduced MACCE incidence with genotype-guided treatment.

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention (PCI) in the Million Veterans Program

This study examines the association between CYP2C19 polymorphisms and major adverse cardiac events after PCI in patients with ACS or SIHD, finding no significant overall association but a numerical increase in risk for ACS patients.

EXPRESSION OF VARIABILITY OF THE CYP2C19*2 GENE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION FROM A SOUTH AMERICAN HOSPITAL AND ITS FUTURE RELEVANCE IN THE INTERACTION BETWEEN GENETICS AND CARDIOLOGY.

The paper examines the frequency of the CYP2C19*2 polymorphism in South American ACS patients and its implications for clopidogrel response.

The role of CYP2C19 gene polymorphisms on antiplatelet activity of clopidogrel among Arabs: systematic review and meta-analysis

This study investigates the impact of CYP2C19 polymorphisms on clopidogrel efficacy in Arabs, finding increased risk of recurrent cardiovascular events in carriers of CYP2C19*2 and *3 alleles.

Genetic variation in activating clopidogrel: longer-term outcomes in a large community cohort

This study finds that CYP2C19 loss-of-function variants are associated with increased risk of ischemic stroke and MI in patients on long-term clopidogrel therapy in primary care.

New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin

This study identifies six new genetic variants associated with major adverse cardiovascular events in ACS patients on dual antiplatelet therapy and develops a predictive classifier for MACE.

CYP2C19*2, CYP2C19*17 and ITGB3 (PlA1/A2) polymorphisms and resulting therapeutic alterations of clopidogrel and aspirin: A clinical screening among CVD patients who undergone PCI

The paper investigates genetic polymorphisms in CYP2C19 and ITGB3 genes and their impact on clopidogrel and aspirin efficacy in cardiovascular patients post-PCI.

A Propensity-Matched Nested Case-Control Study of Acute Coronary Syndrome Patients Genotyped for CYP2C19

This study evaluates the outcomes of acute coronary syndrome patients genotyped for CYP2C19, comparing personalized antiplatelet therapy with ticagrelor and clopidogrel.